[Correction by L-dopa of neurologic manifestations of a chronic portocaval encephalopathy].
D000437:Alcoholism / Q000150:complications; D000641:Ammonia / Q000097:blood; D001927:Brain Diseases / Q000150:complications*; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D004569:Electroencephalography; D006801:Humans; D007656:Ketoglutaric Acids / Q000627:therapeutic use; D007792:Lactulose / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009461:Neurologic Manifestations; D009952:Ornithine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012829:Silicosis / Q000150:complications; D014202:Tremor / Q000188:drug therapy* / Q000209:etiology
D007656:Ketoglutaric Acids; D007792:Lactulose; D004295:Dihydroxyphenylalanine; D000641:Ammonia; D009952:Ornithine; D011241:Prednisone
Correction par la L-Dopa des manifestations neurologiques d'une encéphalopathie porto-cave chronique.